select a format

Single User License
USD 2000 INR 128580
Site License
USD 4000 INR 257160
Corporate User License
USD 6000 INR 385740

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Bullous Pemphigoid-Pipeline Review, H2 2016

Bullous Pemphigoid-Pipeline Review, H2 2016


  • Products Id :- GMDHC8901IDB
  • |
  • Pages: 39
  • |
  • December 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Bullous Pemphigoid-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bullous Pemphigoid-Pipeline Review, H2 2016, provides an overview of the Bullous Pemphigoid (Dermatology) pipeline landscape.

Bullous pemphigoid is a chronic, inflammatory, subepidermal, blistering disease. If untreated, it can persist for monthsor years, with periods of spontaneous remissions and exacerbations. The disease can be fatal, particularly in patientswho are debilitated.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bullous Pemphigoid-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bullous Pemphigoid (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bullous Pemphigoid (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Bullous Pemphigoid and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 1 respectively.

Bullous Pemphigoid (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Bullous Pemphigoid (Dermatology).

The pipeline guide reviews pipeline therapeutics for Bullous Pemphigoid (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Bullous Pemphigoid (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Bullous Pemphigoid (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Bullous Pemphigoid (Dermatology)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Bullous Pemphigoid (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Bullous Pemphigoid (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Bullous Pemphigoid Overview 6

Therapeutics Development 7

Pipeline Products for Bullous Pemphigoid-Overview 7

Bullous Pemphigoid-Therapeutics under Development by Companies 8

Bullous Pemphigoid-Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Bullous Pemphigoid-Products under Development by Companies 11

Bullous Pemphigoid-Companies Involved in Therapeutics Development 12

iCo Therapeutics Inc. 12

Immungenetics AG 13

True North Therapeutics Inc 14

TxCell SA 15

Bullous Pemphigoid-Therapeutics Assessment 16

Assessment by Monotherapy Products 16

Assessment by Target 17

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 22

Drug Profiles 24

bertilimumab-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

dimethyl fumarate-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

ENTX-BP-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Small Molecules for Dermatology, Immunology, Metabolic and CNS Disorders-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

TNT-009-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Bullous Pemphigoid-Dormant Projects 32

Bullous Pemphigoid-Product Development Milestones 33

Featured News & Press Releases 33

Jun 14, 2016: Immune Pharmaceuticals Expands its Bertilimumab Phase II Clinical Trial in Bullous Pemphigoid to Six Academic Institutions in the United States 33

Nov 09, 2015: Immune Pharmaceuticals Announces FDA Acceptance of Investigational New Drug (IND) Application in the U.S. for Bertilimumab for the Treatment of Bullous Pemphigoid 34

Oct 07, 2015: Immune Pharmaceuticals Submits Investigational New Drug Application in the U.S. for its Lead Product Candidate Bertilimumab for the Treatment of Bullous Pemphigoid 34

Jul 13, 2015: Immune Pharmaceuticals to present bertilimumab at The International Eosinophil Society workshop on Personalized Medicine 35

Jun 25, 2015: Immune Pharmaceuticals Initiates Phase II Clinical Trials With Bertilimumab In Ulcerative Colitis And Bullous Pemphigoid 35

Mar 31, 2015: Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 36

Feb 05, 2015: Immune Pharmaceuticals To Present At The BIO CEO & Investor Conference 37

Dec 09, 2014: CEO Dr. Daniel Teper of Immune Pharmaceuticals to Be Interviewed Live on Clear Channel-iHeart Business Talk Radio-December 9, 2014 37

Jul 30, 2014: Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 37

Appendix 38

Methodology 38

Coverage 38

Secondary Research 38

Primary Research 38

Expert Panel Validation 38

Contact Us 38

Disclaimer 39

List of Figures

Number of Products under Development for Bullous Pemphigoid, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy Products, H2 2016 16

Number of Products by Targets, H2 2016 17

Number of Products by Stage and Targets, H2 2016 17

Number of Products by Mechanism of Actions, H2 2016 19

Number of Products by Stage and Mechanism of Actions, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 21

Number of Products by Molecule Types, H2 2016 22

Number of Products by Stage and Molecule Types, H2 2016 22

List of Tables

Number of Products under Development for Bullous Pemphigoid, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Bullous Pemphigoid-Pipeline by iCo Therapeutics Inc., H2 2016 12

Bullous Pemphigoid-Pipeline by Immungenetics AG, H2 2016 13

Bullous Pemphigoid-Pipeline by True North Therapeutics Inc, H2 2016 14

Bullous Pemphigoid-Pipeline by TxCell SA, H2 2016 15

Assessment by Monotherapy Products, H2 2016 16

Number of Products by Stage and Target, H2 2016 18

Number of Products by Stage and Mechanism of Action, H2 2016 20

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 23

Bullous Pemphigoid-Dormant Projects, H2 2016 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

iCo Therapeutics Inc., Immungenetics AG, True North Therapeutics Inc, TxCell SA

Bullous Pemphigoid Therapeutic Products under Development, Key Players in Bullous Pemphigoid Therapeutics, Bullous Pemphigoid Pipeline Overview, Bullous Pemphigoid Pipeline, Bullous Pemphigoid Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com